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Introduction 
Rhabdomyosarcoma (RMS) and neuroblastoma
(NBL) are common soft tissue tumours of childhood.
The results of therapy including surgery and
aggressive chemotherapy are still unsatisfactory. In
RMS, the prognosis is associated with a histological
type (embryonal including botryoides and alveolar),
age of patients and clinical stage at diagnosis. In
clinical stage I and II, the survival (3-year failure free)
is 60-80% of patients while in stage IV this number
decreases to 20-30% [1, 2]. The relapses are
generally associated with a therapy failure and further
decrease in patients’ survival [1, 2]. In recent years,
the intensified chemotherapy has improved results of
therapy but they are still below those expected.
Moreover, the expression of multidrug resistance
(MDR) proteins (glycoprotein p – p-gp, multidrug
resistance related protein 1 – MRP1, breast cancer
resistance protein – BCRP and lung resistance
protein – LRP) is recognized as an additional
unfavourable marker for therapy and prognosis [3-5].
The long-time survival in NBL depends on the
clinical stage, age of patients, n-Myc amplification and
presence of tumour markers [6]. In an advanced stage
and high-risk disease, the survival remains low despite
the most aggressive therapy, including an intensified
chemotherapy protocol, surgery of the primary
tumour and ablative therapy before bone marrow
transplantation [6]. A list of known unfavourable
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The activity of multidrug resistance (MDR) proteins in tumour cells is associated
with an increased resistance to therapy and in consequence with a decreased
effectiveness of chemotherapy. The majority of MDR molecules belong to a family
of ABC (ATP binding cassette) transporters. Neuroblastoma (NBL) and
rhabdomyosarcoma (RMS) are common solid tumours of childhood. The response
to therapy is better in NBL, worse in RMS, but still unsatisfactory despite surgery
and aggressive chemotherapy. The immunohistochemical staining for p-gp 
(p-glycoprotein), MRP1 (multidrug resistance associated protein 1), BCRP (breast
cancer resistance protein) and LRP (lung resistance protein) expression was
performed in primary tumour sections of NBL (10 cases) and RMS (10 cases).
A different pattern of MDR expression in NBL and RMS were noted. In NBL,
MRP1 was expressed in all studied tumours, p-gp, BCRP only in 3 out of 10
tumours, LRP, in 4 cases. The combination of more than one protein was noted in
the majority of NBL tumours. In RMS, the expression of 3 or 4 MDR proteins was
noted in 9 cases. The high expression of an MDR protein profile in RMS suggests
various mechanisms acting simultaneously, which might explain chemotherapy
resistance and a low percentage of long-time survival in this tumour.
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factors in NBL includes the age (more than 1 year of
age), advanced clinical stage, high level of tumour
markers (ferritin, lactodehydrogenase – LDH, neuron
specific enolase – NSE), high number of n-Myc copies
and expression of MDR proteins (mainly MRP and
LRP) [6-8]. 
The study of MDR proteins concentrates on
common proteins, i.e. p-gp (MDR1), MRP1, BCRP
and LRP. The p-gp and MRP1 belong to ATP cassette
binding transporters with the activity of 
a drug efflux pump which exports selected substrates
(including chemotherapeutics) from the cells. BCRP
protein is a half-transporter with mitoxanthrone as the
main substrate. LRP belongs to vault proteins with an
activity resulting in reduction in the intracellular level
of drugs. In the physiology, LRP is expressed in many
tissues including suprarenal gland and muscles –
tissues of NBL and RMS origin. The precise
mechanism of LRP activity is not known [9-13].
A list of p-gp substrates includes alkaloid of Vinca
rosacea, daunorubicin and derivatives, mitoxanthrone
and etoposide [11, 12]. The physiological expression
of p-gp was noted in many tissues including liver,
kidney, hematopoietic cells, jejunum and placenta.
The MRP1 molecules were found in the cell
membrane, in Golgi structures and plasmatic
reticulum. The first known substrate of MRP1 is
mitoxanthrone but all drugs conjugated to acidic
ligands during the intracellular transport and
metabolism may be a target for this molecule [12-14].  
The occurrence of p-gp in RMS is within the wide
range of patients’ number. The intensity of expression
is different in reported groups of patients. The
methods used in these studies may be responsible for
these different results. However, the high expression is
strongly associated with shorter survival of patients 
[3, 10]. The expression of MRP1 was associated with
an alveolar type of RMS, which might be an additional
factor explaining poorer results in this histological type
of the tumour [3]. In NBL cells, the p-gp was noted
in about 80% of patients and was considered as most
common MDR proteins in this tumour. The role of 
p-gp in therapy resistance of tumour cells was
indicated following the observation of an increased 
p-gp expression after chemotherapy in metastases or
relapsing tumour cells [10, 15]. The high expression of
MRP1 was associated with a high number of n-MYC
copies and poor prognosis in NBL [7] but this study
included analysis of MRP1 gene expression only. The
high level of n-MYC seems to promote the expression
and activity of MRP1, which suggests the synergistic
mechanism of an increased resistance to therapy [8, 16].
The purpose of this study was to determine the
expression of different MDR proteins (p-gp, MRP1,
BCRP, LRP) and to analyse the association between
their expression in NBL and RMS primary tumour
cells in children.
Material and methods
Groups of patients included 10 cases of RMS and
10 cases of NBL. The diagnosis of RMS and NBL was
based on histology of the tumour and expression of
desmin, MyoD protein (for RMS), NSE (for NBL) in
malignant cells. The clinical characteristics of patients
are shown in Table I.
The paraffin-embedded sections from primary
tumour biopsies were used. After de-paraffinisation
the sections were stained with monoclonal antibodies
for the following MDR proteins:
• p-gp (Multidrug Resistance protein 1) with
monoclonal antibody (mAb) clone JSB-1 (Monosan,
Uden, Netherlands)  in 1 : 100 working dilution,
overnight incubation,
• BCRP (Breast Cancer Resistance Protein) with
mAb clone BXP-21 (Monosan) in 1 : 150 working
dilution, 2 hrs of incubation,
• mRP1 (Multidrug Resistance Related Protein) with
mAb clone MRPr1 (Monosan) in 1 : 100 working
dilution, 2 hrs of incubation,
Table I. The characteristics of patients with RMS and NBL included into the study
TUMOUR GENDER AGE HISTOLOGICAL LOCALIZATION
BOYS/GIRLS YEARS (MEAN) TYPE OF THE PRIMARY TUMOUR
RMS 6/4 < 1-3 years – 3 embryonal – 8 nose and pharynx – 2
4-10 years – 6 alveolar – 2 pelvis (bladder, anal region) – 5 
teenagers – 1 abdomen – 1
(6.4 years) testes and epididymides – 2 
NBL 6/4 < 1-3 years – 6 neuroblastoma – 10 mediastinal mass – 3
4-10 years – 2 abdomen (retroperitoneal) – 4
teenagers – 2 suprarenal gland – 2
(4.7 years) femur – 1
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• LRP (Lung Resistance Protein) with mAb clone
LRP-56 (Monosan) in 1 : 50 working dilution, 2 hrs
of incubation.
The visualization of reaction was performed with
DakoCytomation EnVision+ system HRP (DAB)
(DAKO, Glostrup, Denmark) according to the
manufacturer’s instruction. The microscopic analysis
included at least 300 cells and was performed by 2
independent investigators. The expression of a given
protein was considered when no less than 10% of
malignant cells showed positive reaction. The results
are expressed as a percentage of positive cells and
intensity of expression is described as: weakly positive
(+), positive (++), strongly positive (+++).
Results
The expression of p-gp in tumour cells was noted in
7 cases: 3 cases of NBL and 4 cases of RMS. The
intensity was low with the exception of 1 case of RMS
(strong reaction). The expression of BCRP was noted
only in 3 cases of NBL and all cases of RMS. The
intensity of expression in NBL cells was low in contrast
to RMS tumour cells, which showed high intensity in
the majority of cases – 8 out of 10 (Fig. 1). MRP1
expression was seen as granular type reaction from
single granule (weak reaction) to cytoplasm filled by
granules (high expression). In both studied tumours
(NBL and RMS), the expression of MRP1 was noted in
all cases but the reaction in NBL cells was rather weak
(5 cases), positive (4 cases) and strong only in 1 case.
The reaction in RMS was much higher and the
expression regarded as positive was noted in 4 cases,
strongly and very strongly positive – in 4 cases. The
weak reaction was noted only in the remaining 2 cases
(Fig. 2). The expression of LRP protein was observed in
6 cases of NBL and 9 cases of RMS. The reaction in
both groups varied and ranged from weak to strong.
MRP1 expression on NBL cells. The intensity was strong
– (++)
Fig. 1. Expression of multidrug resistance (MDR) proteins in neuroblastoma (NBL) primary tumour cells. The
immunohistochemical staining with monoclonal antibodies against given proteins was performed in standard conditions
LRP expression on NBL cells. The intensity was very
strong (+++)
P-gp expression on NBL cells. The immunohistochemical
staining showed high intensity – (++)
BCRP expression on NBL cells. The intensity was weak –
(+)
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Rhabdomyosarcoma tumour cells showed the
presence of more than one MDR protein in the
majority of cases. The expression of 3 or 4 different
proteins present simultaneously was noted.
Neuroblastoma cells showed expression of a single
resistance protein (MRP1) or a combination but only
in 4 cases such combination (3 or 4 proteins) was
present (Table II). 
Discussion
The determination of MDR proteins in NBL and
RMS primary tumour tissue showed a different
pattern of their expression. In NBL, the expression of
MRP1 was common while p-gp, BCRP and LRP was
observed in the minority of studied cases. The
combination of more than one protein was noted in
the majority of NBL tumour cases. In RMS almost in
all cases the expression of at least 3 MDR proteins was
noted. The complex expression of MDR proteins in
RMS may be associated with a higher chemotherapy
resistance and lower percentage of long-time survival
in this type of tumour as an additional mechanism.
MRP1 expression on RMS cells The intensity was strong
– (++)
Fig. 2. Expression of multidrug resistance (MDR) proteins in rhabdomyosarcoma (RMS) primary tumour cells. The
immunohistochemical staining with monoclonal antibodies against given proteins was performed in standard conditions
LRP expression on RMS cells. The intensity was very
strong (+++)
P-gp expression on RMS cells. The intensity was strong –
(++)
BCRP expression on RMS cells. The intensity was very
strong (+++)
Table II. Expression and co-expression of MDR proteins
in NBL and RMS primary tumour cells
MULTIDRUG RESISTANCE NBL RMS
PROTEIN PROFILE
p-gp + MRP1 + LRP 2 0
p-gp + BCRP + MRP1 + LRP 1 4
BCRP + MRP1 1 1
BCRP + MRP1 + LRP 1 5
MRP1 3 0
MRP1 + LRP 2 0
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The expression of gene and/or protein of p-gp in
NBL was noted in a wide range of patients depending
on the groups studied [17, 18]. Moreover, in the
majority of these studies no obvious association with
prognosis, metastases formation, and overall, disease-
free survival was noted [15, 17, 18]. The increase of
p-gp expression along the clinical stages of NBL was
suggested in one study [10]. The analysis of NBL
patients with a better and worse prognosis showed
the association of p-gp expression with a better
prognosis but the majority of these patients were
younger than one year. This prognosis might depend
on the age of patients, which seemed to be a better
predictive factor for a good prognosis than expression
of p-gp [18]. In our study of NBL tumour cells, low
expression of p-gp was observed in both aspects – the
number of cases expressing p-gp and low intensity of
staining resembling the amount of p-gp molecules in
a single cell. The study of RMS tumour cells showed
expression of p-gp in a wide range depending on
methods of assay and no association with survival of
patients [3-5]. In two studies concerning 45 patients
(children and adults) and 13 children, the p-gp
expression was high in both aspects – intensity of
staining and a number of cases expressing this MDR
molecule (80%) [4-5]. In our study, the expression of
p-gp was noted only in 4 patients and the intensity of
staining was low.  
MRP1 proteins are now considered as important
for drug resistance in solid tumours. In NBL, the
correlation between expression of MRP1 and
overexpression of the n-MYC gene increased the risk
of therapy failure. Moreover, there were some data
suggesting the regulation of MRP1 expression by the
n-MYC oncogene [8, 16], which might explain the
correlation between expression of MRP and n-MYC.
It suggested the synergistic effect on therapy leading
to shorter survival of patients. In cases with a low
number of n-MYC copies, MRP1 protein remained 
a significant independent prognostic factor for poor
survival of NBL patients [8, 19]. The predictive role
of MRP1 expression was showed in large groups of
209, 206 and 90 NBL patients [7, 8, 19]. However,
in the last study, the level of MRP1 expression (low
or high) was without any clinical significance [19]. In
our study, expression of MRP1 was noted in all cases
of NBL but the intensity of staining was rather low.
MRP1 expression was independent of other MDR
proteins and was noted as a single MDR protein in
NBL cells. It stressed the importance of MRP1
expression in resistance to therapy in this tumour.
In RMS, the expression of MRP1 was noted in
more than half of studied tumours and was present
in both (embryonal and alveolar) histological types.
However, MRP negative cases were of an embryonal
type of RMS only [4-5]. The clinical significance of
MRP1 expression on RMS tumour cells differs
depending on the group of patients. The association
with shorter survival was noted in a study of 23 RMS
patients [3] while no association was observed in
other groups of 13 and 45 RMS patients [4-5]. In
our cases of RMS, expression of MRP1 was showed in
all cases and all of them were in combination with
other MDR proteins.
The clinical significance of LRP expression in RMS
was shown in refractory tumours after chemotherapy
[4-5]. It suggested that primary tumours were
resistant because of p-gp, MRP1 dependent
mechanisms in contrast to chemotherapy-induced
resistance that is based on LRP activity. The lack of
correlation between LRP and p-gp or MRP1
expression indicated different regulation of LRP
expression than other ABC transporters [4-5]. In our
study, expression of LRP was noted in 6 cases of NBL
and almost all cases (9 out of 10) of RMS in primary
tumours before therapy. Moreover, LRP expression
was noted only in combination with other MDR
proteins. These data made it difficult to interpret
clinical significance of a particular MDR protein
(MRP1 or LRP) in studied tumours. There are no
data about expression of BCRP in NBL and RMS
primary tumours in children. In our study, expression
of BCRP was found in 3 cases of NBL and all cases of
RMS but in combination with other MDR proteins.
The studies of the profile of MDR proteins
expression in primary tumour are scarce 
[3-5]. However, the same relations between these
proteins were found e.g. p-gp correlated with MRP
expression in RMS tumours [5]. The expression of
combination (profile) of MDR proteins indicates 
a different defensive mechanism activity in the same
single tumour cell, which significantly increases
possibility of a tumour cell to survive. In RMS,
expression of MDR proteins was only in combination
mainly with MRP1, BCRP and LRP. The activity of
a wide range of MDR proteins might be associated
with resistance of primary tumour cells and cells
after induction therapy (chemotherapy-induced
resistance) to the majority of cytostatics used in RMS
and NBL treatment.
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